|
SEPT10 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.74280000045479E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.69640000002858E-06 |
| Normal-vs-Stage2 |
2.17399999999923E-05 |
| Normal-vs-Stage3 |
1.30300000011907E-07 |
| Normal-vs-Stage4 |
6.69819999465915E-09 |
| Stage1-vs-Stage2 |
1.638210E-01 |
| Stage1-vs-Stage3 |
1.635840E-01 |
| Stage1-vs-Stage4 |
1.171850E-02 |
| Stage2-vs-Stage3 |
6.985000E-01 |
| Stage2-vs-Stage4 |
6.217600E-01 |
| Stage3-vs-Stage4 |
2.812400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.29759999978729E-07 |
| Normal-vs-AfricanAmerican |
2.366500E-02 |
| Normal-vs-Asian |
6.776100E-04 |
| Caucasian-vs-AfricanAmerican |
6.169000E-01 |
| Caucasian-vs-Asian |
6.754000E-01 |
| AfricanAmerican-vs-Asian |
8.813400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.40030000004433E-08 |
| Normal-vs-Female |
1.92190000025683E-07 |
| Male-vs-Female |
2.557000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.9837000000047E-05 |
| Normal-vs-Age(41-60Yrs) |
1.3057000000094E-06 |
| Normal-vs-Age(61-80Yrs) |
6.31410479456918E-11 |
| Normal-vs-Age(81-100Yrs) |
7.743600E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.399640E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.779100E-04 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.051000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.566200E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.340800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.947000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.606100E-02 |
| Classical-VS-Follicular |
1.27159999996351E-06 |
| Classical-VS-Other |
5.446200E-01 |
| Classical-VS-Normal |
2.396800E-04 |
| Tall-VS-Follicular |
1.140840E-01 |
| Tall-VS-Other |
8.603400E-01 |
| Tall-VS-Normal |
2.24799999999359E-05 |
| Follicular-VS-Other |
3.247800E-01 |
| Follicular-VS-Normal |
5.5798032860821E-11 |
| Other-VS-Normal |
2.567600E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.75899994570017E-09 |
| Normal-vs-N1 |
9.34669999952398E-07 |
| N0-vs-N1 |
9.976400E-01 |
|
|
